Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)

PHASE3CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

April 2, 2019

Primary Completion Date

April 16, 2024

Study Completion Date

April 16, 2024

Conditions
Bronchiolitis ObliteransChronic Rejection of Lung TransplantLung Transplant RejectionLung Transplant; ComplicationsLung Transplant Failure and RejectionChronic Lung Allograft Dysfunction
Interventions
DRUG

Liposomal Cyclosporine A

This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm

DRUG

standard of care

Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator.

Trial Locations (36)

3000

Universitair Ziekenhuis Leuven, Leuven

10032

Columbia University Medical Center, New York

15006

Hospital C.H.U.A.C., A Coruña

15232

University of Pittsburgh Medical Center, Pittsburgh

19140

Temple University Hospital, Philadelphia

21201

University of Maryland, Baltimore

21287

Johns Hopkins University Hospital, Baltimore

27710

Duke University Medical Center, Durham

32224

Mayo Clinic Jacksonville, Jacksonville

32608

University of Florida Medical Center, Gainesville

33606

University of South Florida, Tampa

40508

University of Kentucky Albert B. Chandler Hospital, Lexington

43210

Ohio State University Medical Center, Columbus

44195

Cleveland Clinic, Cleveland

46202

Indiana University Health Methodist Hospital, Indianapolis

63110

Barnes-Jewish Hospital, St Louis

75246

Baylor University Medical Center, Dallas

75390

University of Texas Southwestern Medical Center, Dallas

77030

Baylor St. Luke's Medical Center, Houston

Houston Methodist Hospital, Houston

85013

Banner Health, Phoenix

90095

UCLA Medical Center, Los Angeles

94143

UC San Francisco, San Francisco

94305

Stanford University Hospital, Palo Alto

Unknown

Hôpitaux Universitaires de Strasbourg, Strasbourg

Hannover Medical School - MHH Klinik für Pneumologie, Hanover

LMU Klinikum Großhadern, Munich

Rabin Medical Center, Petah Tikva

Complexo Hospitalario de A Coruna, A Coruña

Hospital Universitari Vall d'Hebron, Barcelona

Hospital Universitario Puerta de Hierro, Madrid

Hospital Marques de Valdecilla, Santander

Hospital Universitario y Politécnico La Fe, Valencia

Royal Papworth Hospital NHS Foundation Trust, Cambridge

University Hospital of South Manchester NHS Foundation Trust, Manchester

Wythenshawe Hospital - Cardiothoracic Transplant Unit, Manchester

All Listed Sponsors
lead

Zambon SpA

INDUSTRY

NCT03657342 - Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) | Biotech Hunter | Biotech Hunter